Andrew Combs - Dec 20, 2024 Form 4 Insider Report for Prelude Therapeutics Inc (PRLD)

Role: Chief Chemistry Officer
Signature: /s/ Krishna Vaddi, Attorney-in-Fact
Stock symbol: PRLD
Transactions as of: Dec 20, 2024
Transactions value $: $85,538
Form type: 4
Date filed: 12/26/2024, 07:49 AM
Previous filing: Mar 4, 2024

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	PRLD	Common Stock	Purchase	$3.54K	+3.08K	+0.98%	$1.15	318K	Dec 20, 2024	Direct	F1
transaction	PRLD	Common Stock	Purchase	$82K	+60K	+18.89%	$1.37	378K	Dec 23, 2024	Direct	F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	The reported total includes 10,106 shares of common stock the reporting person has acquired since the date of his last ownership report through the issuer's Employee Stock Purchase Plan in one or more transactions exempt pursuant to Rules 16b-3(c).
F2	The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $1.20 to $1.55, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth herein.

Content

The reported total includes 10,106 shares of common stock the reporting person has acquired since the date of his last ownership report through the issuer's Employee Stock Purchase Plan in one or more transactions exempt pursuant to Rules 16b-3(c).

The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $1.20 to $1.55, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth herein.